• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Atox Bio Announces Exercise by BARDA of Next Option Period for NSTI Treatment americanpharmaceuticalreview
    June 20, 2019
    Atox Bio announced the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections (NSTI).
  • Atox Bio Announces Chief Commercial Officer Appointment americanpharmaceuticalreview
    February 18, 2019
    Atox Bio announced the appointment of Robert Greif as Chief Commercial Officer. In this newly created position, Greif will be responsible for building the commercial organization and pre-commercial activities for Reltecimod....

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service